News - Valeant Pharmaceuticals


Current filters:

Valeant Pharmaceuticals

Popular Filters

46 to 56 of 56 results

BioDelivery pain drug Onsolis to launch in Canada via Meda Valeant


US specialty drug firm BioDelivery Sciences International (Nasdaq: BDSI) says that its pain drug Onsolis…

BioDelivery SciencesMarkets & MarketingMedaMeda ValeantNeurologicalNorth AmericaOnsolisPharmaceuticalValeant Pharmaceuticals

Valeant posts rocketing sales and earnings for 2nd-qtr 2011


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter…

FinancialGenericsPharmaceuticalTrobaltValeant Pharmaceuticals

EU Commission clears KKR acquisition of Pfizer Capsugel unit; Meda says no approach from Valeant


Under European Union merger regulations, the European Commission has cleared the proposed acquisition…

CapsugelMedaMergers & AcquisitionsPfizerPharmaceuticalValeant Pharmaceuticals

Valeant back on takeover path, now eyeing Sweden’s Meda: Canada OKs Sublinox


Unconfirmed press reports indicate that Canada’s Valeant Pharmaceutical International (NYSE: VRX)…

Markets & MarketingMedaNeurologicalNorth AmericaPharmaceuticalRegulationSublinoxValeant Pharmaceuticals

Valeant to acquire J&J’s Ortho Dermatologics for $345 million


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

DermatologicalsJohnson & JohnsonMergers & AcquisitionsOrtho-McNeil-JanssenPharmaceuticalValeant Pharmaceuticals

Valeant to buy Sanofi’s skin care unit Dermik for $425 million


Canada’s Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to acquire…

DermatologicalsDermikMergers & AcquisitionsNorth AmericaPharmaceuticalSanofiValeant Pharmaceuticals

Medivir renegotiates deal with Meda, receiving $45 million for US rights for Xerese; Meda passes this and Elidel to Valeant


Infectious disease specialist Medivir AB (OMX: MVIR) says that it has renegotiated the terms of its commercial…

Antibiotics and Infectious diseasesElidelLicensingMedaMedivirPharmaceuticalValeant PharmaceuticalsXerese

GlaxoSmithKline and Valeant get FDA approval for epilepsy drug Potiga


Following backing from a US Food and Drug Administration advisory panel last summer (The Pharma Letter…

GlaxoSmithKlineNeurologicalNorth AmericaPharmaceuticalPotigaRegulationTrobaltValeant Pharmaceuticals

Valeant to acquire Lithuanian generics firm Sanitas for around 314 million euros


Canada’s Valeant Pharmaceuticals International (TSX: VRX), which was recently spurned in its $5.7…

GenericsMergers & AcquisitionsPharmaceuticalSanitasValeant Pharmaceuticals

Cephalon accepts Teva’s $6.8 billion takeover, again snubbing Valiant’s $5.7 billion bid


US biotechnology firm Cephalon (Nasdaq: CEPH) has agreed to accept Israel generics giant Teva Pharmaceutical…

BiotechnologyCephalonMergers & AcquisitionsPharmaceuticalTeva Pharmaceutical IndustriesValeant Pharmaceuticals

46 to 56 of 56 results

Back to top